Heart Failure Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multi-centre, Sequential Design, Phase IIa Study to Evaluate Safety and Tolerability of Epicardial Injections of AZD8601 During Coronary Artery Bypass Grafting Surgery
Verified date | August 2021 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four (24) patients scheduled for elective bypass surgery will be randomized (up to approximately 33 patients if replacements are needed). The objective is to investigate safety and tolerability of AZD8601 following epicardial injection in patients undergoing Coronary Artery Bypass Grafting (CABG) surgery with moderately impaired systolic function. At Visit 3 patients will receive either AZD8601 or placebo as epicardial injections and will then be followed up at 14 days (telephone visit) and 1, 3 and 6 months (on-site) post-surgery.
Status | Completed |
Enrollment | 11 |
Est. completion date | June 30, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: For inclusion in the study patients should fulfil the following criteria at Visit 1 and/or 2: 1. Provision of signed and dated informed consent prior to any study specific procedures Males and females: 1. Males must be surgically sterile or using an acceptable method of contraception 2. Females must be of non-childbearing potential confirmed at screening by fulfilling one of the following criteria a) postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the postmenopausal range, b) documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation 3. Age >18 years 4. Indication for elective CABG surgery enrolled at least 15 days before the planned surgery 5. Moderately reduced global LVEF at rest (30% = LVEF = 50%) from medical records 6. If patient is on statin, ACE inhibitor/ARB, and/or beta-blocker, the dose should be stable at least 2 weeks prior to Visit 1 7. Patients who are blood donors should not donate blood during the study and for 3 months following their last dose of AZD8601. Exclusion Criteria: Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) 2. Previous randomisation in the present study 3. Participation in another clinical study with an investigational product during the last 3 months 4. BMI > 35 kg/m2 OR poor image window for echocardiography 5. Need for CABG emergency operation. (Emergency operation is defined as significant symptom status worsening in CAD, such as crescendo angina, unstable angina or ACS requiring rescheduling the revascularization. CAD should be stable at least 3 months prior to Visit 3.) 6. History of ventricular arrhythmia (= Lown III) without Implantable Cardiac Defibrillator (ICD) History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study 8. Severe co-morbidities that can interfere with the execution of the study, interpretation of study results or affect the safety of the patient, in judgement of the investigator 9. eGFR = 30 mL/min (derived from creatinine clearance, calculated by local lab) 10. For CFVR (Visit 1) and sMBF (Visit 2) measurement: - Known severe adverse reactions to adenosine - Known elevated intracranial pressure - AV block = second degree and/or sick sinus syndrome in patient without pacemaker - Heart rate < 40 bpm (ECG verified) - Systolic blood pressure < 90 mmHg - Asthma or COPD with strong reactive component in judgement of investigator - Treatment with dipyridamole (e.g. Persantin or Asasantin), theophyllamine or fluvoxamine that cannot be paused 11. Inability to comply with the protocol 12. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class as study drugs 13. Patients unable to give their consent or communicate reliably with the investigator or vulnerable patients e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order 14. Positive hepatitis C antibody hepatitis B virus surface antigen or hepatitis B virus core antibody or human immunodeficiency virus, at Visit 1 15. Known history of drug or alcohol abuse 16. Any concomitant medications that are known to be associated with Torsades de Pointes 17. History of QT prolongation associated with other medications that required discontinuation of that medication 18. Congenital long QT syndrome 19. History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE Grade 3). 20. Current atrial fibrillation as well as paroxysmal atrial fibrillation. |
Country | Name | City | State |
---|---|---|---|
Finland | Research Site | Kuopio | |
Finland | Research Site | Tampere | |
Finland | Research Site | Turku | |
Germany | Research Site | München | |
Germany | Research Site | München | |
Netherlands | Research Site | Groningen |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Finland, Germany, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serious Adverse Events | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from signing of ICF at Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Adverse event | To assess safety and tolerability of AZD8601 given as epicardial injections | 6 months, from receiving IP at Visit 3 until 6 months after receiving IP. | |
Primary | Electrocardiogram (ECG, number of patients with ECG results exceeding ICH reference ranges) | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Left ventricular ejection fraction (LVEF) change from baseline (%) | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Changes in physical examination (number of abnormal findings in physical examination) | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Changes in vital signs - blood pressure (mmHg) | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Changes in vital signs - pulse (bpm) | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Changes in laboratory values - hematology | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Changes in laboratory values - clinical chemistry | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. | |
Primary | Changes in laboratory values - urinalysis | To assess safety and tolerability of AZD8601 given as epicardial injections | Up to 9 months; from Visit 1, maximum 90 days before investigational product (IP) administration, until 6 months after receiving IP. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|